If you or a family member has been diagnosed with oropharyngeal cancer — cancer of the tonsil, base of tongue, or soft palate — you will likely be told that there are two main treatment options: surgery (specifically TORS — transoral robotic surgery) or radiation therapy. Both can achieve cure in early-stage disease. The question is which is right for you.
This is a question I discuss with patients every week in my clinic. There is no single correct answer — the right choice depends on tumour factors, patient factors, HPV status, and personal priorities. What I want to do in this article is lay out the honest comparison so you can have an informed conversation with your treatment team.
TORS (Transoral Robotic Surgery) uses a surgical robot to remove throat tumours through the mouth — no external incision, 2–3 day hospital stay, and fast return to swallowing. Dr. Narayana Subramaniam is among the pioneers of TORS in India.
Head-to-Head Comparison: TORS vs Radiation
| Factor | TORS Surgery | Radiation Therapy |
|---|---|---|
| Cancer control (T1–T2) | Equivalent — 90%+ local control | Equivalent — 90%+ local control |
| Treatment duration | Single procedure, 1–2 hours | 6–7 weeks daily treatment |
| Hospital stay | 2–3 days | Usually outpatient |
| Return to work | 2–4 weeks | 8–10 weeks (during + after RT) |
| Swallowing side effects | Short-term, usually resolves | Can be long-term — fibrosis |
| Voice effects | Minimal for oropharynx | Possible dryness/change |
| Radiation preserved for future | ✓ Yes — if recurrence | ✗ No — cannot repeat |
| Pathology confirmation | ✓ Yes — margins confirmed | ✗ No tissue analysis |
| De-escalation possible | ✓ Reduced RT if clear margins | Standard dose required |
| Long-term dry mouth | ✓ Avoided or reduced | Common — parotid exposure |
The HPV Factor — Why It Changes Everything
The rise of HPV-positive oropharyngeal cancer has fundamentally changed how we approach treatment. HPV-positive cancers have significantly better outcomes than HPV-negative cancers — 5-year survival rates of 85–90% vs 45–50% — and this has led to active research into whether we can reduce treatment intensity (de-escalation) without sacrificing cure rates.
TORS offers a unique advantage here. When a TORS resection achieves clear margins in an HPV-positive patient with no adverse pathological features, there is a strong argument — supported by growing evidence — for reducing or even omitting adjuvant radiation. This is not possible with primary radiation, which requires a full course regardless of HPV status.
For the right HPV-positive patient, TORS followed by reduced-dose radiation or observation may mean avoiding the worst long-term side effects of full-dose radiation — particularly chronic dry mouth (xerostomia) and swallowing fibrosis — while maintaining excellent cancer control.
When TORS is Preferred
TORS is generally preferred when the tumour is small and accessible (T1–T2), when the patient wants to preserve radiation as a future option, when pathological confirmation of clear margins is important for treatment planning, when the patient is HPV-positive and may qualify for radiation de-escalation, and when the patient wants the shortest possible active treatment period.
When Radiation is Preferred
Primary radiation is generally preferred when the tumour is large or involves structures that make TORS technically difficult, when bilateral neck disease makes surgery complex, when the patient has significant comorbidities that increase surgical risk, or when the patient strongly prefers to avoid any surgical procedure.
What Patients Often Don't Realise About Radiation
Radiation therapy for oropharyngeal cancer is not without significant side effects — particularly in the long term. Xerostomia (permanent dry mouth) affects up to 70% of patients after full-dose radiation. Radiation fibrosis can cause progressive swallowing difficulty years after treatment. Osteoradionecrosis of the jaw — though uncommon — is a serious complication that can require further surgery.
Radiation is also a one-time resource. Once used in an area, it cannot be safely repeated. If cancer recurs after primary radiation, the treatment options are significantly more limited — and salvage surgery in a previously irradiated field is technically much more demanding.
TORS, by contrast, preserves radiation for use if needed in the future — giving patients more treatment options if disease recurs.
My Approach to This Decision
When I see a patient with oropharyngeal cancer in my clinic, I present both options honestly, with their respective evidence. I believe strongly that patients should make this decision with full information — not be steered toward one approach because it is more convenient for the treating team.
At our multidisciplinary tumour board, every case is reviewed jointly by surgical oncology, radiation oncology, and medical oncology before a recommendation is made. Patients then discuss options with me directly before deciding.
Dr. Narayana Subramaniam
Early adopter of TORS in India. Trained at world-class centres including the University of Pennsylvania. Consultation within 48 hours.
WhatsApp for ConsultationGet a Second Opinion on Your Treatment Plan
WhatsApp your reports and imaging — preliminary opinion within 4 hours. Most patients seen within 48–72 hours.